Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.

CONCLUSIONS: Alosetron 1 mg BID significantly reduced healthcare utilization and lost productivity and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP. PMID: 30293448 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research